about
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptorQuality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancerProspective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction.Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).Safety distance in the resection of colorectal lung metastases: a prospective evaluation of satellite tumor cells with immunohistochemistry.Optimized retroviral transduction protocol for human progenitor cells utilizing fibronectin fragments.Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.Surgical treatment of Klatskin tumor: liver resection versus transplantation.[Adjuvant therapy in colon cancer].Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Cancer patients and the Internet: a survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie.Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference?Novel prognostic scoring system after surgery for Klatskin tumor.Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.[Laparoscopic surgery and adjuvant therapy for colon cancer].[Adjuvant therapy of colon carcinoma].Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group.Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.Ten-year survival of esophageal cancer after an en-bloc esophagectomy.Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.[Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology].Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project.A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancerLong-term survival after "liver first" approach for locally advanced rectal cancer and synchronous liver metastasesOperations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patientsPrognostic impact of intrahepatic lymphatic and microvascular involvement in cases of colorectal liver metastasesAn open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancerPhase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomasRectal cancer and synchronous metastases: resection of primary tumor or not?Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumoursDevelopment and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS)
P50
Q28236797-503F80E0-1413-4DC2-9493-A24DBC48DBE3Q30313818-7852F3AA-1388-4B68-BD59-010D366B5AA0Q30317428-AD398250-DD97-4296-AAD4-096983F7E539Q34468886-6AE852AA-D67E-413A-9950-A8317D6D7E32Q34581435-14E18F20-4A09-4F90-B250-D435BCE7D326Q34660081-4A02C03D-8A2A-4339-BFA2-269B715DEC9CQ37639724-377AA455-5B61-433D-A172-47BAEE9AF296Q37780040-469A1EA9-DEA2-4A9B-A7FD-E6D5074068B9Q37861450-042267CF-4F7A-4D23-BF16-A477BEDA2BADQ38661921-813A71D0-73EA-48E0-81CA-98C9EFC1E774Q39804795-28F6F81D-652D-4D47-8664-E1391063D541Q40727927-85407910-2F6D-402F-95A8-385FF2201BFBQ41233808-46EB1347-DBD2-4985-8B50-31008557A580Q42744532-662D9DE8-5C83-42D9-AB85-DAD45005E0F2Q43079179-35865792-E3B1-4E96-86A5-D17DA643A500Q43136630-5F7DD008-5979-4BC9-92C9-D346D3CE79BBQ44740157-4910510E-DC40-469F-8F39-749B15F16BDAQ44912931-618A6335-9CB8-419F-BB39-CAB0AB748C55Q45048493-2B545D92-B7D1-40A1-8CA2-AA3F1947E377Q45785465-84D03F31-07E1-4CCA-BBDC-12865B23610CQ45958009-1B40FBE3-CE2A-40EF-BB3D-1DD700B0D015Q46228705-E10B425F-5FC5-47F3-A9E2-65FA04629B07Q46339959-88B0C915-91BD-4814-99B3-5EF5D1405D1BQ50710931-EABBD701-123E-4D79-9A48-084362F1169DQ51005345-C49F8080-A997-44BB-8D44-388FE9D166D4Q52630749-9D8BC30F-3F42-430D-953C-B6B77777C813Q54624824-DC5ADCCA-0EA4-4AD7-846E-129DC53488C5Q64940373-E0E634E7-1E5F-43A8-A519-7F8708EFA021Q79546010-1EC6CCEF-AB02-404C-8A94-64BD674D20BEQ82905112-0EBA7B1D-FEE7-4509-92B5-748D3A0A154CQ83378985-9E676943-3582-4C37-AED7-0D5294A975ECQ83394173-C6C12DA3-37F2-426C-A3EB-9EABD64A9B89Q84077312-76BC7FA1-9ECA-4C28-9A23-F085C03D84B4Q84523134-C3BAE3CC-001C-4F8E-AA96-38F99C18EFB6Q84961186-C1815261-F3C3-4A01-B535-7DECC511D381Q85076690-922C14C5-F16C-4C39-8D55-2FEE1DD37AE6Q92133922-8A6B8CAC-83BD-495C-AB01-D39192635431
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tanja Trarbach
@ast
Tanja Trarbach
@en
Tanja Trarbach
@es
Tanja Trarbach
@nl
type
label
Tanja Trarbach
@ast
Tanja Trarbach
@en
Tanja Trarbach
@es
Tanja Trarbach
@nl
prefLabel
Tanja Trarbach
@ast
Tanja Trarbach
@en
Tanja Trarbach
@es
Tanja Trarbach
@nl
P1053
F-4944-2019
P106
P31
P496
0000-0002-1275-4040